Gratia Husada Farma is primarily engaged in pharmaceutical preparations, nec activity. Its headquarters is located in Jawa Tengah. The company was founded in 1974. Gratia Husada Farma, commonly known as Graha Farma, was founded by Dr. H. Soedjono Hoemardani and has grown to become a significant player in the Indonesian pharmaceutical industry. The company focuses on the production and distribution of a wide range of pharmaceutical products, including over-the-counter medications, prescription drugs, and health supplements. Graha Farma operates several branches across Indonesia, with a strong presence in major cities such as Jakarta, Surabaya, and Bandung. The company's product portfolio includes well-known brands like Grahavit, Grahacet, and Grahavit C, which cater to various health needs ranging from vitamins to pain relief. In addition to its domestic operations, Graha Farma exports its products to several countries in Southeast Asia, contributing to its growing international footprint. The company is committed to maintaining high standards of quality and safety in its manufacturing processes, adhering to Good Manufacturing Practices (GMP) and other international standards. Graha Farma collaborates with various healthcare organizations and participates in joint ventures to enhance its research and development capabilities. The company is a member of the Indonesian Pharmaceutical Association and actively engages in initiatives to improve public health and access to medicines. With a vision to become a leading pharmaceutical company in the region, Graha Farma is dedicated to innovation and excellence in healthcare, striving to improve the quality of life for people through its products and services.
Headquarters
Kawasan Industri Candi Blok V No 11
Ungaran; Central Java;
Postal Code: 50184
Contact Details: Purchase the PT Gratia Husada Farma report to view the information.
Website: http://www.hufa.co.id
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service